XNAS · INMB
+3.28% · +$0.0600 · Vol 91.6K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
INmune Bio Inc. Common stock

INmune Bio Inc. Common stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$1.89
Card
Relationship Map

Follow $INMB

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $INMB by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
INMB
INmune Bio Inc. Common stock
Fri Oct 9 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

70/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Fri Oct 9 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is INMB moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading INMB catalysts
About INmune Bio Inc. Common stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2019
Employees
21
Country
US

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.84
Day high
$1.91
Day low
$1.84
Previous close
$1.83
52W high
$2.51
-24.70% from high
52W low
$1.12
55% of range
Market cap
$50.8M
Beta
2.52
Shares out
27.8M
Volume
91.6K
0.29× rel vol
Avg volume
315K
VWAP
$1.88
Price history computed in-house
1W
-2.07%
1M
-18.18%
3M
-2.58%
1Y
+1.61%
YTD
+21.15%
SMA 50 $2.13 · below
SMA 200 $1.64 · above
52W position 55%

INMB overview

Veridion Score
70
Registered · 2026-10-09
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around INMB.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading INMB Form 4 filings
Public disclosures

Congress activity in INMB

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

INMB contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for INMB in this window.
Lobbying spend

INMB lobbying filings, year to date.

Registered lobbying filings matched to INmune Bio Inc. Common stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for INMB in this window.
Loading news for INMB
Analyst ratings
Sovereign unlock shows live analyst consensus for INMB.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.